Special issue: Empowering eHealth with smart internet of things (IoT) medical devices

[No abstract available]Scopu

Sub-micron surface plasmon resonance sensor systems

A sensor for detecting the presence of a target analyte, ligand or molecule in a test fluid, comprising a light transmissive substrate on which an array of surface plasmon resonant (SPR) elements is mounted is described. A multi-channel sensor for detecting the presence of several targets with a single micro-chip sensor is described. A multi-channel sensor including collections of SPR elements which are commonly functionalized to one of several targets is also described. The detectors sense changes in the resonant response of the SPR elements indicative of binding with the targets

Sub-micron surface plasmon resonance sensor systems

A sensor for detecting the presence of a target analyte, ligand or molecule in a test fluid, comprising a light transmissive substrate on which an array of surface plasmon resonant (SPR) elements is mounted is described. A multi-channel sensor for detecting the presence of several targets with a single micro-chip sensor is described. A multi-channel sensor including collections of SPR elements which are commonly functionalized to one of several targets is also described. The detectors sense changes in the resonant response of the SPR elements indicative of binding with the targets

Translating electrochemical aptamer-based sensors to real-world applications

By coupling the specific and selective binding of biomolecules with conformation-linked signaling and electrochemical outputs, electrochemical aptamer-based sensors (E-AB sensors) provide a unique ability to measure molecules in real-time directly in complex media. Because E-AB sensors do not require washing steps or reagent additions, they open the door for measurements directly where they are needed – in complex sample streams such as foodstuffs, clinical samples, and even directly within the living body. To further advance this promising technology, my work has addressed both improvements in the physical sensor and improvements in how we use the electron transfer kinetics underlying the signaling in these sensors to circumvent the drift associated with performing measurements directly in complex media. That is, using new electrode formats and new analytical signal-processing techniques, my thesis work created fully realized devices capable of measuring specific molecular targets in real time in relevant, highly complex sample streams. As examples, in my thesis I describe sensors supporting the measurement of a mycotoxin directly within the flowing sample stream of a foodstuff affected by that mycotoxin, the measurement of a malaria diagnostic protein in clinically-relevant ranges directly in a fingerprick-sized sample of human serum, a new technique to measure a protein of interest directly in unprocessed whole blood – without pre-calibration, and new deployments of thin, surgically-implanted wire electrodes with sensors that measure, for the first time, in vivo blood concentrations in real time of a variety of small-molecule drugs as well as an arbitrary circulating protein of interest

Industrial-Scale Manufacture of Oleosin 30G for Use as Contrast Agent in Echocardiography

In ultrasound sonography, microbubbles are used as contrasting agents to improve the effectiveness of ultrasound imaging. Monodisperse microbubbles are required to achieve the optimal image quality. In order to achieve a uniform size distribution, microbubbles are stabilized with surfactant molecules. One such molecule is Oleosin, an amphiphilic structural protein found in vascular plant oil bodies that contains one hydrophobic and two hydrophilic sections. Controlling the functionalization of microbubbles is a comprehensive and versatile process using recombinant technology to produce a genetically engineered form of Oleosin called Oleosin 30G. With the control of a microfluidic device, uniformly-sized and resonant microbubbles can be readily produced and stored in stable conditions up to one month. Currently, Oleosin microbubbles are limited to the lab-scale; however, through development of an integrated batch bioprocessing model, the overall product yield of Oleosin 30G can be increased to 7.39 kg/year to meet needs on the industrial-scale. An Oleosin-stabilized microbubble suspension as a contrast agent is in a strong position to take a competitive share of the current market, capitalizing on needs unmet by current market leader, Definity®. Based on market dynamics and process logistics, scaled-up production of Oleosin 30G for use as a contrast agent is expected to be both a useful and profitable venture

Optimization of Oleosin 30G Production for Echocardiography

Provided they are uniform in size, monodisperse microbubbles behave as contrast agents to enhance echocardiographic imaging. Compounds like Oleosin 30G with surfactant-like properties help stabilize microbubbles - thereby ensuring their uniform size. Designed herein is an industrial-scale plant to produce medical-grade Oleosin 30G with a process consisting of three steps: 1) upstream production via recombinant E. coli in an integrated batch bioprocessing model, 2) downstream purification, and 3) processing by microfluidic manifolds. Ultimately Oleosin 30G-coated microbubbles are manufactured, ready for injection within one month. Owing to its unique properties and cost-effective production, Oleosin 30G has the potential to outcompete current market leader Definity®. Altogether, overall yield of Oleosin 30G constitutes 7.39 kg/year to provide for 100% market saturation. Financial analysis indicates pursuing Oleosin 30G for echocardiography applications is very profitable with a 296% return on investment and holds potential for production expansion should the market demand increase